Annual CFF
-$12.13 M
-$9.30 M-327.71%
December 31, 2023
Summary
- As of February 12, 2025, HBIO annual cash flow from financing activities is -$12.13 million, with the most recent change of -$9.30 million (-327.71%) on December 31, 2023.
- During the last 3 years, HBIO annual CFF has fallen by -$4.17 million (-52.30%).
- HBIO annual CFF is now -122.87% below its all-time high of $53.05 million, reached on December 31, 2018.
Performance
HBIO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$2.10 M
+$1.93 M+1088.70%
September 30, 2024
Summary
- As of February 12, 2025, HBIO quarterly cash flow from financing activities is $2.10 million, with the most recent change of +$1.93 million (+1088.70%) on September 30, 2024.
- Over the past year, HBIO quarterly CFF has increased by +$4.85 million (+176.51%).
- HBIO quarterly CFF is now -95.89% below its all-time high of $51.24 million, reached on March 31, 2018.
Performance
HBIO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
-$2.89 M
+$4.85 M+62.68%
September 30, 2024
Summary
- As of February 12, 2025, HBIO TTM cash flow from financing activities is -$2.89 million, with the most recent change of +$4.85 million (+62.68%) on September 30, 2024.
- Over the past year, HBIO TTM CFF has increased by +$7.86 million (+73.11%).
- HBIO TTM CFF is now -105.45% below its all-time high of $53.05 million, reached on December 31, 2018.
Performance
HBIO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
HBIO Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -327.7% | +176.5% | +73.1% |
| 3 y3 years | -52.3% | +332.0% | -665.6% |
| 5 y5 years | -122.9% | +419.8% | +62.1% |
HBIO Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -4715.1% | at low | -18.9% | +151.1% | -196.9% | +76.2% |
| 5 y | 5-year | -4715.1% | at low | -37.3% | +139.7% | -196.9% | +76.2% |
| alltime | all time | -122.9% | at low | -95.9% | +116.9% | -105.5% | +80.4% |
Harvard Bioscience Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $2.10 M(+1088.7%) | -$2.89 M(-62.7%) |
| Jun 2024 | - | $177.00 K(-116.8%) | -$7.74 M(-24.8%) |
| Mar 2024 | - | -$1.05 M(-74.4%) | -$10.30 M(-15.1%) |
| Dec 2023 | -$12.13 M(+327.7%) | -$4.12 M(+49.7%) | -$12.13 M(+12.9%) |
| Sep 2023 | - | -$2.75 M(+15.8%) | -$10.75 M(+41.0%) |
| Jun 2023 | - | -$2.38 M(-17.9%) | -$7.62 M(+30.9%) |
| Mar 2023 | - | -$2.89 M(+6.0%) | -$5.82 M(+105.3%) |
| Dec 2022 | -$2.84 M(+1025.8%) | -$2.73 M(-824.1%) | -$2.84 M(-214.1%) |
| Sep 2022 | - | $377.00 K(-165.2%) | $2.49 M(-4.2%) |
| Jun 2022 | - | -$578.00 K(-714.9%) | $2.60 M(-12.9%) |
| Mar 2022 | - | $94.00 K(-96.4%) | $2.98 M(-1283.7%) |
| Dec 2021 | -$252.00 K(-96.8%) | $2.59 M(+432.6%) | -$252.00 K(-149.3%) |
| Sep 2021 | - | $487.00 K(-353.6%) | $511.00 K(-155.0%) |
| Jun 2021 | - | -$192.00 K(-93.9%) | -$929.00 K(-84.6%) |
| Mar 2021 | - | -$3.14 M(-193.6%) | -$6.04 M(-24.2%) |
| Dec 2020 | -$7.97 M(+4.5%) | $3.36 M(-452.3%) | -$7.97 M(-32.2%) |
| Sep 2020 | - | -$953.00 K(-82.0%) | -$11.75 M(+2.6%) |
| Jun 2020 | - | -$5.30 M(+4.5%) | -$11.46 M(+49.0%) |
| Mar 2020 | - | -$5.07 M(+1082.1%) | -$7.69 M(+0.9%) |
| Dec 2019 | -$7.62 M(-114.4%) | -$429.00 K(-34.8%) | -$7.62 M(+1.0%) |
| Sep 2019 | - | -$658.00 K(-57.1%) | -$7.55 M(+80.2%) |
| Jun 2019 | - | -$1.53 M(-69.4%) | -$4.19 M(+31.1%) |
| Mar 2019 | - | -$5.00 M(+1313.6%) | -$3.19 M(-106.0%) |
| Dec 2018 | $53.05 M(-3060.5%) | -$354.00 K(-113.1%) | $53.05 M(+0.2%) |
| Sep 2018 | - | $2.70 M(-601.3%) | $52.97 M(+6.9%) |
| Jun 2018 | - | -$539.00 K(-101.1%) | $49.54 M(-0.4%) |
| Mar 2018 | - | $51.24 M(<-9900.0%) | $49.72 M(-2874.6%) |
| Dec 2017 | -$1.79 M(-63.2%) | -$439.00 K(-39.4%) | -$1.79 M(-30.1%) |
| Sep 2017 | - | -$724.00 K(+100.6%) | -$2.56 M(-10.5%) |
| Jun 2017 | - | -$361.00 K(+34.7%) | -$2.86 M(-16.0%) |
| Mar 2017 | - | -$268.00 K(-77.9%) | -$3.41 M(-30.0%) |
| Dec 2016 | -$4.87 M(+801.5%) | -$1.21 M(+18.2%) | -$4.87 M(+1.0%) |
| Sep 2016 | - | -$1.02 M(+12.8%) | -$4.82 M(+14.6%) |
| Jun 2016 | - | -$908.00 K(-47.4%) | -$4.21 M(+35.8%) |
| Mar 2016 | - | -$1.73 M(+48.7%) | -$3.10 M(+473.7%) |
| Dec 2015 | -$540.00 K(-56.2%) | -$1.16 M(+182.5%) | -$540.00 K(+13.0%) |
| Sep 2015 | - | -$411.00 K(-305.5%) | -$478.00 K(-136.9%) |
| Jun 2015 | - | $200.00 K(-76.0%) | $1.30 M(+145.2%) |
| Mar 2015 | - | $832.00 K(-175.7%) | $529.00 K(-142.9%) |
| Dec 2014 | -$1.23 M(-1914.7%) | -$1.10 M(-180.6%) | -$1.23 M(-90.2%) |
| Sep 2014 | - | $1.36 M(-340.1%) | -$12.61 M(-14.4%) |
| Jun 2014 | - | -$568.00 K(-39.0%) | -$14.73 M(+229.9%) |
| Mar 2014 | - | -$931.00 K(-92.5%) | -$4.46 M(-6666.2%) |
| Dec 2013 | $68.00 K(-106.4%) | -$12.48 M(+1561.7%) | $68.00 K(-99.4%) |
| Sep 2013 | - | -$751.00 K(-107.7%) | $12.02 M(-0.1%) |
| Jun 2013 | - | $9.70 M(+169.2%) | $12.03 M(+579.1%) |
| Mar 2013 | - | $3.60 M(-787.4%) | $1.77 M(-266.7%) |
| Dec 2012 | -$1.06 M | -$524.00 K(-29.2%) | -$1.06 M(+149.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2012 | - | -$740.00 K(+30.7%) | -$426.00 K(+16.1%) |
| Jun 2012 | - | -$566.00 K(-173.8%) | -$367.00 K(-169.6%) |
| Mar 2012 | - | $767.00 K(+578.8%) | $527.00 K(-146.2%) |
| Dec 2011 | -$1.14 M(+3580.6%) | $113.00 K(-116.6%) | -$1.14 M(-2.2%) |
| Sep 2011 | - | -$681.00 K(-307.6%) | -$1.17 M(-137.3%) |
| Jun 2011 | - | $328.00 K(-136.4%) | $3.13 M(+443.2%) |
| Mar 2011 | - | -$901.00 K(-1135.6%) | $576.00 K(-1958.1%) |
| Dec 2010 | -$31.00 K(-100.3%) | $87.00 K(-97.6%) | -$31.00 K(-100.7%) |
| Sep 2010 | - | $3.62 M(-262.5%) | $4.32 M(-53.0%) |
| Jun 2010 | - | -$2.23 M(+47.5%) | $9.20 M(-6.7%) |
| Mar 2010 | - | -$1.51 M(-133.9%) | $9.86 M(+0.8%) |
| Dec 2009 | $9.79 M(-223.0%) | $4.44 M(-47.7%) | $9.79 M(+311.0%) |
| Sep 2009 | - | $8.49 M(-643.6%) | $2.38 M(-139.6%) |
| Jun 2009 | - | -$1.56 M(-1.3%) | -$6.01 M(+45.0%) |
| Mar 2009 | - | -$1.58 M(-46.6%) | -$4.15 M(-47.9%) |
| Dec 2008 | -$7.96 M(-362.5%) | -$2.96 M(-3319.6%) | -$7.96 M(+297.6%) |
| Sep 2008 | - | $92.00 K(-69.9%) | -$2.00 M(-454.8%) |
| Jun 2008 | - | $306.00 K(-105.7%) | $564.00 K(-163.7%) |
| Mar 2008 | - | -$5.39 M(-280.2%) | -$885.00 K(-129.2%) |
| Dec 2007 | $3.03 M(-157.3%) | $2.99 M(+12.6%) | $3.03 M(+2654.5%) |
| Sep 2007 | - | $2.66 M(-332.5%) | $110.00 K(-101.8%) |
| Jun 2007 | - | -$1.14 M(-22.6%) | -$6.01 M(-11.6%) |
| Mar 2007 | - | -$1.48 M(-2150.0%) | -$6.80 M(+28.6%) |
| Dec 2006 | -$5.29 M(-32.2%) | $72.00 K(-102.1%) | -$5.29 M(-53.2%) |
| Sep 2006 | - | -$3.46 M(+79.7%) | -$11.30 M(+32.3%) |
| Jun 2006 | - | -$1.93 M(-5770.6%) | -$8.54 M(+30.8%) |
| Mar 2006 | - | $34.00 K(-100.6%) | -$6.53 M(-16.2%) |
| Dec 2005 | -$7.79 M(-285.1%) | -$5.95 M(+748.4%) | -$7.79 M(+169.2%) |
| Sep 2005 | - | -$701.00 K(-944.6%) | -$2.90 M(+19.1%) |
| Jun 2005 | - | $83.00 K(-106.8%) | -$2.43 M(-37.8%) |
| Mar 2005 | - | -$1.23 M(+17.1%) | -$3.90 M(-192.7%) |
| Dec 2004 | $4.21 M(-67.7%) | -$1.05 M(+344.5%) | $4.21 M(-64.5%) |
| Sep 2004 | - | -$236.00 K(-83.0%) | $11.87 M(-8.6%) |
| Jun 2004 | - | -$1.39 M(-120.2%) | $12.99 M(-7.0%) |
| Mar 2004 | - | $6.89 M(+4.1%) | $13.97 M(+7.0%) |
| Dec 2003 | $13.05 M(-515.1%) | $6.61 M(+651.6%) | $13.05 M(+114.2%) |
| Sep 2003 | - | $880.00 K(-316.7%) | $6.09 M(+17.2%) |
| Jun 2003 | - | -$406.00 K(-106.8%) | $5.20 M(+176.5%) |
| Mar 2003 | - | $5.97 M(-1829.3%) | $1.88 M(-159.8%) |
| Dec 2002 | -$3.15 M(-132.4%) | -$345.00 K(+2056.3%) | -$3.15 M(-284.0%) |
| Sep 2002 | - | -$16.00 K(-99.6%) | $1.71 M(-4.8%) |
| Jun 2002 | - | -$3.73 M(-495.9%) | $1.80 M(-64.9%) |
| Mar 2002 | - | $941.00 K(-79.1%) | $5.12 M(-47.2%) |
| Dec 2001 | $9.70 M(-73.4%) | $4.51 M(+6342.0%) | $9.70 M(+86.9%) |
| Sep 2001 | - | $70.00 K(-117.4%) | $5.19 M(+1.4%) |
| Jun 2001 | - | -$402.00 K(-107.3%) | $5.12 M(-7.3%) |
| Mar 2001 | - | $5.52 M | $5.52 M |
| Dec 2000 | $36.52 M(+422.3%) | - | - |
| Dec 1999 | $6.99 M | - | - |
FAQ
- What is Harvard Bioscience annual cash flow from financing activities?
- What is the all time high annual CFF for Harvard Bioscience?
- What is Harvard Bioscience annual CFF year-on-year change?
- What is Harvard Bioscience quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Harvard Bioscience?
- What is Harvard Bioscience quarterly CFF year-on-year change?
- What is Harvard Bioscience TTM cash flow from financing activities?
- What is the all time high TTM CFF for Harvard Bioscience?
- What is Harvard Bioscience TTM CFF year-on-year change?
What is Harvard Bioscience annual cash flow from financing activities?
The current annual CFF of HBIO is -$12.13 M
What is the all time high annual CFF for Harvard Bioscience?
Harvard Bioscience all-time high annual cash flow from financing activities is $53.05 M
What is Harvard Bioscience annual CFF year-on-year change?
Over the past year, HBIO annual cash flow from financing activities has changed by -$9.30 M (-327.71%)
What is Harvard Bioscience quarterly cash flow from financing activities?
The current quarterly CFF of HBIO is $2.10 M
What is the all time high quarterly CFF for Harvard Bioscience?
Harvard Bioscience all-time high quarterly cash flow from financing activities is $51.24 M
What is Harvard Bioscience quarterly CFF year-on-year change?
Over the past year, HBIO quarterly cash flow from financing activities has changed by +$4.85 M (+176.51%)
What is Harvard Bioscience TTM cash flow from financing activities?
The current TTM CFF of HBIO is -$2.89 M
What is the all time high TTM CFF for Harvard Bioscience?
Harvard Bioscience all-time high TTM cash flow from financing activities is $53.05 M
What is Harvard Bioscience TTM CFF year-on-year change?
Over the past year, HBIO TTM cash flow from financing activities has changed by +$7.86 M (+73.11%)